Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics

Sattler S, Mehlkop G, Graeff P, Sauer C (2014)
Substance Abuse Treatment, Prevention, and Policy 9(1): 8.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA
Autor*in
Sattler, Sebastian; Mehlkop, Guido; Graeff, Peter; Sauer, CarstenUniBi
Abstract / Bemerkung
Background The use of cognitive enhancement (CE) by means of pharmaceutical agents has been the subject of intense debate both among scientists and in the media. This study investigates several drivers of and obstacles to the willingness to use prescription drugs non-medically for augmenting brain capacity. Methods We conducted a web-based study among 2,877 students from randomly selected disciplines at German universities. Using a factorial survey, respondents expressed their willingness to take various hypothetical CE-drugs; the drugs were described by five experimentally varied characteristics and the social environment by three varied characteristics. Personal characteristics and demographic controls were also measured. Results We found that 65.3% of the respondents staunchly refused to use CE-drugs. The results of a multivariate negative binomial regression indicated that respondents’ willingness to use CE-drugs increased if the potential drugs promised a significant augmentation of mental capacity and a high probability of achieving this augmentation. Willingness decreased when there was a high probability of side effects and a high price. Prevalent CE-drug use among peers increased willingness, whereas a social environment that strongly disapproved of these drugs decreased it. Regarding the respondents’ characteristics, pronounced academic procrastination, high cognitive test anxiety, low intrinsic motivation, low internalization of social norms against CE-drug use, and past experiences with CE-drugs increased willingness. The potential severity of side effects, social recommendations about using CE-drugs, risk preferences, and competencies had no measured effects upon willingness. Conclusions These findings contribute to understanding factors that influence the willingness to use CE-drugs. They support the assumption of instrumental drug use and may contribute to the development of prevention, policy, and educational strategies.
Stichworte
Cognitive test anxiety; Academic procrastination; Risk attitudes; Social network; Social norms; Substance abuse; Pharmaceutical cognitive enhancement
Erscheinungsjahr
2014
Zeitschriftentitel
Substance Abuse Treatment, Prevention, and Policy
Band
9
Ausgabe
1
Art.-Nr.
8
ISSN
1747-597X
Page URI
https://pub.uni-bielefeld.de/record/2660085

Zitieren

Sattler S, Mehlkop G, Graeff P, Sauer C. Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics. Substance Abuse Treatment, Prevention, and Policy. 2014;9(1): 8.
Sattler, S., Mehlkop, G., Graeff, P., & Sauer, C. (2014). Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics. Substance Abuse Treatment, Prevention, and Policy, 9(1), 8. doi:10.1186/1747-597X-9-8
Sattler, S., Mehlkop, G., Graeff, P., and Sauer, C. (2014). Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics. Substance Abuse Treatment, Prevention, and Policy 9:8.
Sattler, S., et al., 2014. Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics. Substance Abuse Treatment, Prevention, and Policy, 9(1): 8.
S. Sattler, et al., “Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics”, Substance Abuse Treatment, Prevention, and Policy, vol. 9, 2014, : 8.
Sattler, S., Mehlkop, G., Graeff, P., Sauer, C.: Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics. Substance Abuse Treatment, Prevention, and Policy. 9, : 8 (2014).
Sattler, Sebastian, Mehlkop, Guido, Graeff, Peter, and Sauer, Carsten. “Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics”. Substance Abuse Treatment, Prevention, and Policy 9.1 (2014): 8.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Copyright Statement:
This Item is protected by copyright and/or related rights. [...]
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2019-09-06T09:18:21Z
MD5 Prüfsumme
3bb4f9d2da7b6c418519f76879f3a465

11 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Use and Propensity to Use Substances as Cognitive Enhancers in Italian Medical Students.
Pighi M, Pontoni G, Sinisi A, Ferrari S, Mattei G, Pingani L, Simoni E, Galeazzi GM., Brain Sci 8(11), 2018
PMID: 30423911
Work-related stress and cognitive enhancement among university teachers.
Wiegel C, Sattler S, Göritz AS, Diewald M., Anxiety Stress Coping 29(1), 2016
PMID: 25747817
Pharmacological Cognitive Enhancement in Healthy Individuals: A Compensation for Cognitive Deficits or a Question of Personality?
Maier LJ, Wunderli MD, Vonmoos M, Römmelt AT, Baumgartner MR, Seifritz E, Schaub MP, Quednow BB., PLoS One 10(6), 2015
PMID: 26107846
Swiss University Students' Attitudes toward Pharmacological Cognitive Enhancement.
Maier LJ, Liakoni E, Schildmann J, Schaub MP, Liechti ME., PLoS One 10(12), 2015
PMID: 26657300
Attitudes toward pharmacological cognitive enhancement-a review.
Schelle KJ, Faulmüller N, Caviola L, Hewstone M., Front Syst Neurosci 8(), 2014
PMID: 24860438

102 References

Daten bereitgestellt von Europe PubMed Central.

[Pharmacological neuroenhancement and brain doping : Chances and risks].
Franke AG, Lieb K., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53(8), 2010
PMID: 20700786
Psychopharmacological enhancment
AUTHOR UNKNOWN, 2008
[Options, limits and ethics of pharmacological neuroenhancement].
Normann C, Boldt J, Maio G, Berger M., Nervenarzt 81(1), 2010
PMID: 19851745
Antidepressants for neuro enhancement in healthy individuals: a systematic review
AUTHOR UNKNOWN, 2009
Use of cognitive enhancement medication among northern Italian university students.
Castaldi S, Gelatti U, Orizio G, Hartung U, Moreno-Londono AM, Nobile M, Schulz PJ., J Addict Med 6(2), 2012
PMID: 22456492
Cognitive enhancement, lifestyle choice or misuse of prescription drugs?
AUTHOR UNKNOWN, 2010
Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany.
Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, Hildt E, Lieb K., Pharmacopsychiatry 44(2), 2010
PMID: 21161883
Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications.
Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, Wang GJ, Jayne M, Hooker JM, Wong C, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog-Torres K., JAMA 301(11), 2009
PMID: 19293415
Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers.
Winder-Rhodes SE, Chamberlain SR, Idris MI, Robbins TW, Sahakian BJ, Muller U., J. Psychopharmacol. (Oxford) 24(11), 2009
PMID: 19493958
'Smart drugs': do they work? Are they ethical? Will they be legal?
Rose SP., Nat. Rev. Neurosci. 3(12), 2002
PMID: 12461554
Cognitive enhancement by drugs in health and disease.
Husain M, Mehta MA., Trends Cogn. Sci. (Regul. Ed.) 15(1), 2010
PMID: 21146447
Towards responsible use of cognitive-enhancing drugs by the healthy.
Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ., Nature 456(7223), 2008
PMID: 19060880
Professor's little helper.
Sahakian B, Morein-Zamir S., Nature 450(7173), 2007
PMID: 18097378
The nonmedical use of prescription ADHD medications: results from a national Internet panel.
Novak SP, Kroutil LA, Williams RL, Van Brunt DL., Subst Abuse Treat Prev Policy 2(), 2007
PMID: 17974020
Misuse of "study drugs:" prevalence, consequences, and implications for policy.
Sussman S, Pentz MA, Spruijt-Metz D, Miller T., Subst Abuse Treat Prev Policy 1(), 2006
PMID: 16764722
Illicit use of prescription stimulants in a college student sample: a theory-guided analysis.
Bavarian N, Flay BR, Ketcham PL, Smit E., Drug Alcohol Depend 132(3), 2013
PMID: 23683794
Academic strain and non-medical use of prescription stimulants among college students
AUTHOR UNKNOWN, 2009
Motives and perceived consequences of nonmedical ADHD medication use by college students: are students treating themselves for attention problems?
Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS., J Atten Disord 13(3), 2008
PMID: 18664714
Nonmedical prescription stimulant use among a sample of college students: relationship with psychological variables.
Weyandt LL, Janusis G, Wilson KG, Verdi G, Paquin G, Lopes J, Varejao M, Dussault C., J Atten Disord 13(3), 2009
PMID: 19767596
Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration.
Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ., Pharmacotherapy 26(10), 2006
PMID: 16999660
Rational choice theory and empirical research: methodological and theoretical contributions in Europe
AUTHOR UNKNOWN, 2012
Rational Choice Theory in Sociology: a survey
AUTHOR UNKNOWN, 2000
The rationale for consuming cognitive enhancement drugs in university students and teachers.
Sattler S, Sauer C, Mehlkop G, Graeff P., PLoS ONE 8(7), 2013
PMID: 23874778
Cognitive effects of modafinil in student volunteers may depend on IQ.
Randall DC, Shneerson JM, File SE., Pharmacol. Biochem. Behav. 82(1), 2005
PMID: 16140369
Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: a pilot study
AUTHOR UNKNOWN, 2012
Rational addiction and the effect of price on consumption
AUTHOR UNKNOWN, 1991
What price drug use? The contribution of economics to an evidence-based drugs policy
AUTHOR UNKNOWN, 2004
The social contagion effect of marijuana use among adolescents.
Ali MM, Amialchuk A, Dwyer DS., PLoS ONE 6(1), 2011
PMID: 21264337

AUTHOR UNKNOWN, 2008
Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences.
Mache S, Eickenhorst P, Vitzthum K, Klapp BF, Groneberg DA., Wien Med Wochenschr 162(11-12), 2012
PMID: 22707077
A Decision-Making Approach to Opioid Addiction
AUTHOR UNKNOWN, 1986
Using social networks to understand and prevent substance use: a transdisciplinary perspective.
Valente TW, Gallaher P, Mouttapa M., Subst Use Misuse 39(10-12), 2004
PMID: 15587948
Conscience, significant others, and rational choice: extending the deterrence model
AUTHOR UNKNOWN, 1990
Modeling Sutherland’s theory of differential association: toward an empirical clarification
AUTHOR UNKNOWN, 1986
Perceptual deterrence and the mediating effect of internalized norms among inner-city teenagers
AUTHOR UNKNOWN, 1997
Academic procrastination of undergraduates: Low self-efficacy to self-regulate predicts higher levels of procrastination
AUTHOR UNKNOWN, 2008
Longitudinal study of procrastination, performance, stress, and health: the costs and benefits of dawdling
AUTHOR UNKNOWN, 1997
Anxiety and performance: the processing efficiency theory
AUTHOR UNKNOWN, 1992
Anxiety and cognitive performance: attentional control theory.
Eysenck MW, Derakshan N, Santos R, Calvo MG., Emotion 7(2), 2007
PMID: 17516812
Commercializing cognitive neurotechnology--the ethical terrain.
Eaton ML, Illes J., Nat. Biotechnol. 25(4), 2007
PMID: 17420741

AUTHOR UNKNOWN, 1997
Test anxiety: interference, defective skills, and cognitive capacity
AUTHOR UNKNOWN, 1985
Approach and avoidance achievement goals and intrinsic motivation: a mediational analysis
AUTHOR UNKNOWN, 1986
Motivation and education: the self-determination perspective
AUTHOR UNKNOWN, 1991
Intrinsic and Extrinsic Motivations: Classic Definitions and New Directions.
Ryan RM, Deci EL., Contemp Educ Psychol 25(1), 2000
PMID: 10620381
Achievement goals in the classroom: students’ learning strategies and motivation processes
AUTHOR UNKNOWN, 1988
Academic Self-Handicapping and Achievement Goals: A Further Examination.
Midgley C, Urdan T., Contemp Educ Psychol 26(1), 2001
PMID: 11161640
Predictors and consequences of achievement goals in the college classroom: maintaining interest and making the grade
AUTHOR UNKNOWN, 1997
Explaining the decision to plagiarize: an empirical test of the interplay between rationality, norms, and opportunity
AUTHOR UNKNOWN, 2013
Cognitive enhancement: methods, ethics, regulatory challenges.
Bostrom N, Sandberg A., Sci Eng Ethics 15(3), 2009
PMID: 19543814
Ethnic pride, biculturalism, and drug use norms of urban American Indian adolescents.
Kulis S, Napoli M, Marsiglia FF., Soc Work Res 26(2), 2001
PMID: 21399737
A focus theory of normative conduct: a theoretical refinement and reevaluation of the role of norms in human behavior
AUTHOR UNKNOWN, 1991
Norms and rationality. Is moral behavior a form of rational action?
AUTHOR UNKNOWN, 2013
Residual effects of past on later behavior: habituation and reasoned action perspectives
AUTHOR UNKNOWN, 2002
Integrating celerity, impulsivity, and extralegal sanction threats into a model of general deterrence: theory and evidence
AUTHOR UNKNOWN, 2001
Habit and intention in everyday life: the multiple processes by which past behavior predicts future behavior
AUTHOR UNKNOWN, 1998
Predictors of nonmedical ADHD medication use by college students.
Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, Swartzwelder HS., J Atten Disord 13(6), 2009
PMID: 19465730
Neurocognitive enhancement: what can we do and what should we do?
Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, King P, Parens E, Sahakian B, Wolpe PR., Nat. Rev. Neurosci. 5(5), 2004
PMID: 15100724
A theory-based dual-focus alcohol intervention for preadolescents: the Strong African American Families Program.
Gerrard M, Gibbons FX, Brody GH, Murry VM, Cleveland MJ, Wills TA., Psychol Addict Behav 20(2), 2006
PMID: 16784365
Reasoned action and social reaction: willingness and intention as independent predictors of health risk.
Gibbons FX, Gerrard M, Blanton H, Russell DW., J Pers Soc Psychol 74(5), 1998
PMID: 9599437
Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration.
Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ., Pharmacotherapy 26(10), 2006
PMID: 16999660
Missing data analysis: making it work in the real world.
Graham JW., Annu Rev Psychol 60(), 2009
PMID: 18652544
Factorial survey methods for studying beliefs and judgments
AUTHOR UNKNOWN, 2006
25 years of factorial surveys in sociology: a review
AUTHOR UNKNOWN, 2009
Experimental plans in factorial surveys: random or quota design?
AUTHOR UNKNOWN, 2007
Individual risk attitudes: measurement, determinants, and behavioural consequences
AUTHOR UNKNOWN, 2011
Theory and measurement of test anxiety as a situation-specific trait
AUTHOR UNKNOWN, 1995
Psychometrische Eigenschaften und Validität des multidimensionalen Prüfungsängstlichkeitsinventars TAI-G
AUTHOR UNKNOWN, 1999
The Tai-G: A Multidimensional Approach to the Assessment of Test Anxiety
AUTHOR UNKNOWN, 1996
Investigating the effect of academic procrastination on the frequency and variety of academic misconduct: a panel study
AUTHOR UNKNOWN, 0
Trait procrastination, time management, and academic behavior
AUTHOR UNKNOWN, 1993
Das Berliner Evaluationsinstrument für selbsteingeschätzte, studentische Kompetenzen
AUTHOR UNKNOWN, 2008

AUTHOR UNKNOWN, 1995

AUTHOR UNKNOWN, 2002
What should we do about student use of cognitive enhancers? An analysis of current evidence.
Ragan CI, Bard I, Singh I; Independent Scientific Committee on Drugs., Neuropharmacology 64(), 2012
PMID: 22732441

AUTHOR UNKNOWN, 2011
Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students.
Dietz P, Striegel H, Franke AG, Lieb K, Simon P, Ulrich R., Pharmacotherapy 33(1), 2013
PMID: 23307544
Nonmedical use of prescription stimulants in the United States.
Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA., Drug Alcohol Depend 84(2), 2006
PMID: 16480836

AUTHOR UNKNOWN, 2012
Sampling weights and regression analysis
AUTHOR UNKNOWN, 1994
The impact of anonymity on responses to sensitive questions
AUTHOR UNKNOWN, 2000
Sensitive questions in surveys.
Tourangeau R, Yan T., Psychol Bull 133(5), 2007
PMID: 17723033
Social desirability bias in CATI, IVR, and Web surveys: the effects of mode and question sensitivity
AUTHOR UNKNOWN, 2008
The use of vignettes in survey research
AUTHOR UNKNOWN, 1978
Designing vignette studies in marketing
AUTHOR UNKNOWN, 2002
An examination of the effects of social desirability bias on business ethics: research results
AUTHOR UNKNOWN, 2002

AUTHOR UNKNOWN, 1998
Writing about testing worries boosts exam performance in the classroom.
Ramirez G, Beilock SL., Science 331(6014), 2011
PMID: 21233387

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 24484640
PubMed | Europe PMC

Suchen in

Google Scholar